Genetics
Novel CETP L296Q mutation discovered and linked to coronary heart disease and higher LDL cholesterol (Acta Biochim Biophys Sin (Shanghai) 2004)
Original title: A novel missense mutation (L296 Q) in cholesteryl ester transfer protein gene related to coronary heart disease
Screening the promoter, all 16 exons, and adjacent intronic regions of the CETP gene in 203 coronary heart disease (CHD) patients and 209 healthy volunteers using PCR, DHPLC, molecular cloning, and sequencing, researchers identified a novel missense mutation, L296Q, caused by a T-to-A change at codon 296 of exon 10 that replaces leucine with glutamine. The mutant 296Q allele frequency was significantly higher in CHD patients than controls (0.160 vs. 0.091, chi-square=9.014, P=0.003), with an odds ratio of 1.83 for CHD in 296Q carriers versus 296LL homozygotes. 296Q carrier patients also had significantly higher total cholesterol and LDL-cholesterol than noncarrier patients, indicating this newly discovered CETP mutation is closely related to CHD risk.
Original abstract
Cholesteryl ester transfer protein (CETP) is a key participant in the reverse transport of cholesterol from the peripheral tissues to the liver. To understand further the role that CETP gene plays in the pathogenesis of coronary heart disease (CHD), the promoter region, all 16 exons and adjacent intronic regions of CETP gene were screened for single nucleotide polymorphisms (SNPs) in 203 CHD patients and 209 healthy volunteers by the combination of PCR, denaturing high performance liquid chromatography (DHPLC), molecular cloning, and DNA sequencing. A novel missense mutation in the CETP gene was identified. This mutation (L(296)Q) was caused by a T-to-A conversion at codon 296 of exon 10 which resulted in the replacing of the codon for leucine (CTG) with the codon for glutamine (CAG). Further studies found that there was a significant increase in the mutant allele frequency in the CHD patients compared with that in the controls (0.160 vs. 0.091,cgr;(2) = 9.014, P = 0.003), and the odds ratio to develop CHD was 1.83 for the (296)Q allele carriers vs. (296)LL homozygotes. Statistical analyses also demonstrated that the mutant (296)Q allele carrier patients displayed significantly higher total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) concentrations than noncarrier patients. All these results suggest that the Q(296) mutation in CETP gene was closely related to CHD, and the identification of new mutations in the CETP gene will afford the opportunity to investigate the relationship between CETP gene and CHD.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.